Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01392326
First received: July 7, 2011
Last updated: June 18, 2014
Last verified: June 2014
  Purpose

This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.


Condition Intervention Phase
Psoriatic Arthritis
Drug: Secukinumab (75 mg)
Drug: Secukinumab (150 mg)
Drug: Placebo Comparator
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Proportion of patients achieving ACR20 response criteria on secukinumab 75 or 150 mg vs. placebo [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of subjects achieving a PASI75 response in the subgroup of subjects who have ≥3% skin involvement with psoriasis [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects achieving a PASI90 response in the subgroup of subjects who have ≥3% skin involvement with psoriasis [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline in DAS28-CRP for secukinumab 75 or 150 mg [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline in SF36-PCS for secukinumab 75 or 150 mg [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline in HAQ-DI for secukinumab 75 or 150 mg [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Proportion of patients achieving ACR50 response criteria on secukinumab 75 or 150 mg vs. placebo [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline for joint/bone structural damage (van der Heijde modified total Sharp score) for secukinumab 75 and 150 mg (pooled doses) [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Proportion of patients with dactylitis in the subset of subjects who have dactylitis at baseline [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Proportion of patients with enthesitis in the subset of subjects who have enthesitis at baseline [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline for joint/bone structural damage (van der Heijde modified total Sharp score) for secukinumab 75 or 150 mg [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Enrollment: 606
Study Start Date: September 2011
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
Secukinumab (75mg)
Drug: Secukinumab (75 mg)
Secukinumab (75 mg)
Experimental: Group 2
Secukinumab (150 mg)
Drug: Secukinumab (150 mg)
Secukinumab (150 mg)
Placebo Comparator: Group 3 Drug: Placebo Comparator
Placebo Comparator

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Male or non-pregnant, non-lactating female patients at least 18 years of age
  • Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)
  • Rheumatoid factor and anti-CCP antibodies negative
  • Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2cm diameter or nail changes consistent with psoriasis or documented history o plaque psoriasis

Exclusion criteria:

  • Chest X-ray with evidence of ongoing infectious or malignant process
  • Subjects who have previously been treated with more than 3 different TNFα inhibitors
  • Subjects taking high potency opioid analgesics
  • Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01392326

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Anniston, Alabama, United States, 36207-5710
United States, Arizona
Novartis Investigative Site
Mesa, Arizona, United States, 85202
Novartis Investigative Site
Paradise Valley, Arizona, United States, 85253
United States, California
Novartis Investigative Site
Upland, California, United States, 91786
United States, Florida
Novartis Investigative Site
Tamarac, Florida, United States, 33321
United States, Georgia
Novartis Investigative Site
Newnan, Georgia, United States, 30263
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States, 02111
United States, Minnesota
Novartis Investigative Site
Eagan, Minnesota, United States, 55121
United States, Missouri
Novartis Investigative Site
Richmond Heights, Missouri, United States, 63117
United States, Nebraska
Novartis Investigative Site
Lincoln, Nebraska, United States, 68516
United States, New Jersey
Novartis Investigative Site
Freehold, New Jersey, United States, 07728
United States, North Carolina
Novartis Investigative Site
Charlotte, North Carolina, United States, 28210
United States, Oklahoma
Novartis Investigative Site
Oklahoma City, Oklahoma, United States, 73103
United States, Pennsylvania
Novartis Investigative Site
Duncansville, Pennsylvania, United States, 16635
United States, Rhode Island
Novartis Investigative Site
Johnston, Rhode Island, United States, 02919
United States, South Carolina
Novartis Investigative Site
Charleston, South Carolina, United States, 29406
Novartis Investigative Site
Columbia, South Carolina, United States, 29204
United States, Tennessee
Novartis Investigative Site
Jackson, Tennessee, United States, 38305
United States, Texas
Novartis Investigative Site
Benbrook, Texas, United States, 76126
Novartis Investigative Site
Dallas, Texas, United States, 75246
Novartis Investigative Site
Dallas, Texas, United States, 75216
Novartis Investigative Site
Houston, Texas, United States, 77074
Novartis Investigative Site
Houston, Texas, United States, 77034
Novartis Investigative Site
Mesquite, Texas, United States, 75150
United States, Washington
Novartis Investigative Site
Seattle, Washington, United States, 98122
Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1181ACH
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1419AHN
Novartis Investigative Site
Rosario, Santa Fe, Argentina, S200BHD
Novartis Investigative Site
Rosario, Santa Fe, Argentina, S2000CFJ
Novartis Investigative Site
Buenos Aires, Argentina, C1417EYG
Novartis Investigative Site
Cordoba, Argentina, X5022CPU
Novartis Investigative Site
Cordoba, Argentina, X5000EOC
Novartis Investigative Site
Cordoba, Argentina, X5016KEH
Australia, Queensland
Novartis Investigative Site
Maroochydore, Queensland, Australia, 4558
Australia, Victoria
Novartis Investigative Site
Malvern, Victoria, Australia, 3144
Belgium
Novartis Investigative Site
Genk, Belgium, 3600
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Leuven, Belgium, 3000
Brazil
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90610-000
Novartis Investigative Site
Sao Paulo, SP, Brazil, 04266-010
Novartis Investigative Site
São Paulo, SP, Brazil, 04023-900
Bulgaria
Novartis Investigative Site
Pleven, Bulgaria, 5800
Novartis Investigative Site
Sevlievo, Bulgaria, 5400
Novartis Investigative Site
Sofia, Bulgaria, 1709
Novartis Investigative Site
Sofia, Bulgaria, 1612
Canada, Newfoundland and Labrador
Novartis Investigative Site
St. John, Newfoundland and Labrador, Canada, A1B 5E8
Novartis Investigative Site
St. John's, Newfoundland and Labrador, Canada, A1C 5B8
Canada, Ontario
Novartis Investigative Site
Newmarket, Ontario, Canada, L3Y 3R7
Novartis Investigative Site
Waterloo, Ontario, Canada, N2J 1C4
Canada, Quebec
Novartis Investigative Site
Trois-Rivieres, Quebec, Canada, G8Z 1Y2
Czech Republic
Novartis Investigative Site
Bruntal, Czech Republic, 792 01
Novartis Investigative Site
Uherske Hradiste, Czech Republic, 686 01
Novartis Investigative Site
Zlin, Czech Republic, 760 01
Germany
Novartis Investigative Site
Aachen, Germany, 52064
Novartis Investigative Site
Berlin, Germany, 12200
Novartis Investigative Site
Erlangen, Germany, 91056
Novartis Investigative Site
Erlangen, Germany, 91054
Novartis Investigative Site
Gommern, Germany, 39245
Novartis Investigative Site
Hamburg, Germany, 22143
Novartis Investigative Site
Hamburg, Germany, 22415
Novartis Investigative Site
Herne, Germany, 44625
Novartis Investigative Site
Hildesheim, Germany, 31134
Novartis Investigative Site
Koeln, Germany, 50924
Novartis Investigative Site
Leipzig, Germany, 04103
Novartis Investigative Site
Nürnberg, Germany, 90429
Novartis Investigative Site
Ratingen, Germany, 40882
Novartis Investigative Site
Zerbst, Germany, 39261
Israel
Novartis Investigative Site
Ashkelon, Israel, 78278
Novartis Investigative Site
Haifa, Israel, 31048
Novartis Investigative Site
Ramat Gan, Israel, 52621
Novartis Investigative Site
Tel-Aviv, Israel, 64239
Italy
Novartis Investigative Site
Valeggio Sul Mincio, (vr), Italy, 37067
Novartis Investigative Site
Catania, CT, Italy, 95100
Novartis Investigative Site
Prato, PO, Italy, 59100
Novartis Investigative Site
Siena, SI, Italy, 53100
Philippines
Novartis Investigative Site
Lipa City, Batangas, Philippines, 4217
Novartis Investigative Site
Dasmarinas, Cavite, Philippines, 4114
Novartis Investigative Site
Manila, Metro Manila, Philippines, 1003
Novartis Investigative Site
Las Pinas, Philippines, 1740
Novartis Investigative Site
Manila, Philippines, 1000
Novartis Investigative Site
Manila, Philippines, 1004
Novartis Investigative Site
Manila, Philippines, 1008
Novartis Investigative Site
Quezon City, Philippines, 1102
Novartis Investigative Site
Quezon City, Philippines, 1121
Poland
Novartis Investigative Site
Bialystok, Poland, 15-351
Novartis Investigative Site
Warszawa, Poland, 02-341
Romania
Novartis Investigative Site
Bucharest, District 1, Romania
Novartis Investigative Site
Bucharest, Romania
Novartis Investigative Site
Cluj Napoca, Romania, 400006
Novartis Investigative Site
Iasi, Romania, 700195
Russian Federation
Novartis Investigative Site
Ekaterinburg, Russian Federation, 620219
Novartis Investigative Site
Ekaterinburg, Russian Federation, 620102
Novartis Investigative Site
Kemerovo, Russian Federation, 650029
Novartis Investigative Site
Moscow, Russian Federation, 115522
Novartis Investigative Site
St-Petersburg, Russian Federation, 190068
Novartis Investigative Site
Yaroslavl, Russian Federation, 150003
Singapore
Novartis Investigative Site
Singapore, Singapore, 529889
Novartis Investigative Site
Singapore, Singapore, 119074
Novartis Investigative Site
Singapore, Singapore, 169608
Slovakia
Novartis Investigative Site
Piestany, Slovak Republic, Slovakia, 921 12
Novartis Investigative Site
Lucenec, Slovakia, 98401
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10400
Novartis Investigative Site
Chiang Mai, Thailand, 50200
Novartis Investigative Site
Khon Kaen, Thailand, 40002
United Kingdom
Novartis Investigative Site
London, England, United Kingdom, E11 1NR
Novartis Investigative Site
Cannock, Staffordshire, United Kingdom, WS11 5XY
Novartis Investigative Site
Bradford, West Yorkshire, United Kingdom, BD5 0NA
Novartis Investigative Site
Glasgow, United Kingdom, G12 8TA
Novartis Investigative Site
London, United Kingdom, SE1 9RT
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01392326     History of Changes
Other Study ID Numbers: CAIN457F2306, 2011-000276-34
Study First Received: July 7, 2011
Last Updated: June 18, 2014
Health Authority: United States: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Brazil: National Health Surveillance Agency
Bulgaria: Bulgarian Drug Agency
Canada: Health Canada
Czech Republic: State Institute for Drug Control
Germany: Federal Institute for Drugs and Medical Devices
Israel: Ministry of Health
Italy: Ethics Committee
Peru: Ministry of Health
Philippines: Department of Health
Poland: Ministry of Health
Romania: National Medicines Agency
Russia: Ministry of Health of the Russian Federation
Singapore: Health Sciences Authority
Slovakia: State Institute for Drug Control
Thailand: Ethical Committee
Turkey: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Novartis:
Psoriatic arthritis
PsA
ACR
CASPAR

Additional relevant MeSH terms:
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 26, 2014